Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report

PURPOSE: To determine the maximum-tolerated or recommended phase II dose, dose-limiting toxicities (DLTs), pharmacokinetics (PK), and immunomodulatory effects of lenalidomide in children with recurrent or refractory solid tumors or myelodysplastic syndrome (MDS). PATIENTS AND METHODS: Cohorts of chi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Berg, Stacey L., Cairo, Mitchell S., Russell, Heidi, Ayello, Janet, Ingle, Ashish Mark, Lau, Henry, Chen, Nianhang, Adamson, Peter C., Blaney, Susan M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2011
Schlagworte:
Original Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3056465/
https://ncbi.nlm.nih.gov/pubmed/21149673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.30.8387
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge